JP2014515349A5 - - Google Patents

Download PDF

Info

Publication number
JP2014515349A5
JP2014515349A5 JP2014511504A JP2014511504A JP2014515349A5 JP 2014515349 A5 JP2014515349 A5 JP 2014515349A5 JP 2014511504 A JP2014511504 A JP 2014511504A JP 2014511504 A JP2014511504 A JP 2014511504A JP 2014515349 A5 JP2014515349 A5 JP 2014515349A5
Authority
JP
Japan
Prior art keywords
halo
alkyl
pharmaceutically acceptable
independently
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014511504A
Other languages
English (en)
Japanese (ja)
Other versions
JP6130827B2 (ja
JP2014515349A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/038215 external-priority patent/WO2012158844A1/en
Publication of JP2014515349A publication Critical patent/JP2014515349A/ja
Publication of JP2014515349A5 publication Critical patent/JP2014515349A5/ja
Application granted granted Critical
Publication of JP6130827B2 publication Critical patent/JP6130827B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014511504A 2011-05-17 2012-05-16 ヘテロ環化合物 Active JP6130827B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161487224P 2011-05-17 2011-05-17
US61/487,224 2011-05-17
PCT/US2012/038215 WO2012158844A1 (en) 2011-05-17 2012-05-16 Heterocyclic compounds

Publications (3)

Publication Number Publication Date
JP2014515349A JP2014515349A (ja) 2014-06-30
JP2014515349A5 true JP2014515349A5 (enExample) 2016-10-27
JP6130827B2 JP6130827B2 (ja) 2017-05-17

Family

ID=47177330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014511504A Active JP6130827B2 (ja) 2011-05-17 2012-05-16 ヘテロ環化合物

Country Status (4)

Country Link
US (1) US9156830B2 (enExample)
EP (1) EP2709609B1 (enExample)
JP (1) JP6130827B2 (enExample)
WO (1) WO2012158844A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2642998B1 (en) 2010-11-24 2020-09-16 The Trustees of Columbia University in the City of New York A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
PE20141531A1 (es) 2011-06-22 2014-10-23 Purdue Pharma Lp Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos
WO2013021276A1 (en) 2011-08-10 2013-02-14 Purdue Pharma L.P. Trpv1 antagonists including dihydroxy substituent and uses thereof
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
CA2901577A1 (en) * 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
WO2014151959A1 (en) * 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US10273243B2 (en) 2013-03-14 2019-04-30 The Trustees Of Columbia University In The City Of New York 4-phenylpiperidines, their preparation and use
ES2700541T3 (es) 2013-03-14 2019-02-18 Univ Columbia Octahidrociclopentapirroles, su preparación y uso
US9944644B2 (en) 2013-03-14 2018-04-17 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles their preparation and use
JP6676541B2 (ja) 2014-04-30 2020-04-08 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 置換された4−フェニルピペリジン、その調製及び使用
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US9447015B1 (en) * 2015-04-15 2016-09-20 Valent Biosciences Corporation (S)-2′-vinyl-abscisic acid derivatives
MY189453A (en) 2015-06-03 2022-02-14 Bristol Myers Squibb Co 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
CN108218848B (zh) * 2018-01-22 2020-12-18 贵州大学 一种三氟甲基吡啶联噁二唑(醚)类衍生物及其应用
JP7050165B2 (ja) 2018-02-26 2022-04-07 ギリアード サイエンシーズ, インコーポレイテッド Hbv複製阻害剤としての置換ピロリジン化合物
EP4613272A1 (en) 2022-10-31 2025-09-10 Shionogi & Co., Ltd Use of pyridine derivative which is trpv1 antagonist

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1261835A (en) 1984-08-20 1989-09-26 Masaaki Toda (fused) benz(thio)amides
US5639754A (en) 1994-07-12 1997-06-17 Janssen Pharmaceutica N.V. Urea and thiourea derivatives of azolones
WO1996011210A1 (en) 1994-10-07 1996-04-18 Fujisawa Pharmaceutical Co., Ltd. Cyclic hexapeptides having antibiotic activity
KR100428601B1 (ko) 1995-06-21 2004-09-16 시오노기세이야쿠가부시키가이샤 비사이클릭아미노유도체및이들을함유하는프로스타글란딘디2길항제
JPH11139969A (ja) * 1997-08-07 1999-05-25 Tanabe Seiyaku Co Ltd 医薬組成物
EP1278755A2 (en) 2000-03-07 2003-01-29 Ranbaxy Laboratories, Limited Azole compounds as therapeutic agents for fungal infections
KR20030024799A (ko) * 2000-07-20 2003-03-26 뉴로젠 코포레이션 캡사이신 수용체 리간드
JP4280073B2 (ja) 2001-04-12 2009-06-17 ファーマコペイア ドラッグ ディスカバリー, インコーポレイテッド Mchアンタゴニストとして使用されるアリールピペリジンおよびビアリールピペリジン
EP1450801A4 (en) 2001-11-27 2010-10-27 Merck Sharp & Dohme 2-aminoquinoline CONNECTIONS
ATE465993T1 (de) 2002-02-01 2010-05-15 Euro Celtique Sa 2-piperazinpyridine für die schmerzbehandlung
US6974818B2 (en) 2002-03-01 2005-12-13 Euro-Celtique S.A. 1,2,5-thiadiazol-3-YL-piperazine therapeutic agents useful for treating pain
BR0312322A (pt) 2002-06-28 2005-04-12 Euro Celtique Sa Compostos, composições, métodos para o tratamento da dor em um animal, da incontinência urinária em um animal, de uma úlcera em um animal, de sìndrome de intestino irritável em um animal, da doença inflamatória do intestino em um animal, métodos para a inibição da função de vr1 em uma célula, kits e métodos para a preparação de uma composição
US7262194B2 (en) 2002-07-26 2007-08-28 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7157462B2 (en) 2002-09-24 2007-01-02 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7582761B2 (en) 2002-10-17 2009-09-01 Amgen Inc. Vanilloid receptor ligands and their use in treatments
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
AR044688A1 (es) 2003-06-12 2005-09-21 Euro Celtique Sa Agentes terapeuticos utiles para el tratamiento del dolor
DE602004020994D1 (de) 2003-07-24 2009-06-18 Euro Celtique Sa Piperidinverbindungen und pharmazeutische zusammensetzungen, die diese enthalten
DE602004021206D1 (de) 2003-07-24 2009-07-02 Euro Celtique Sa Zur Behandlung oder Vorbeugung von Schmerzen geeignete Heteroaryl-Tetrahydropiperidyl-Verbindungen
SI1648880T1 (sl) 2003-08-01 2010-05-31 Euro Celtique Sa Terapevtska sredstva uporabna za zdravljenje bolečine
DE602004031163D1 (de) 2003-09-22 2011-03-03 Euro Celtique Sa Phenylcarboxamidverbindungen zur Schmerzbehandlung
ES2317052T3 (es) 2003-09-22 2009-04-16 Euro-Celtique S.A. Agentes terapeuticos utiles para el tratamiento del dolor.
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE602004019576D1 (de) 2003-12-30 2009-04-02 Euro Celtique Sa Zur behandlung von schmerzen geeignete piperazine
US7605176B2 (en) 2004-03-06 2009-10-20 Boehringer Ingelheim International Gmbh β-ketoamide compounds with MCH antagonistic activity
US7667041B2 (en) 2004-05-26 2010-02-23 Eisai R&D Management Co., Ltd. Cinnamide compound
EP1959944A1 (en) 2005-12-15 2008-08-27 Shionogi Co., Ltd. A pharmaceutical composition comprising an amide derivative
DE102007018151A1 (de) * 2007-04-16 2008-10-23 Günenthal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
CA2685266C (en) 2007-04-27 2014-01-28 Purdue Pharma L.P. Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal
JP5372913B2 (ja) 2007-04-27 2013-12-18 パーデュー、ファーマ、リミテッド、パートナーシップ 疼痛治療に有効な治療薬
JP2011518144A (ja) * 2008-04-17 2011-06-23 ファイザー・インク Faah阻害剤として有用な4−ベンジリデン−3−メチルピペリジンアリールカルボキサミド化合物
ES2617619T3 (es) 2008-06-05 2017-06-19 Janssen Pharmaceutica, N.V. Combinaciones de fármacos que comprenden un inhibidor de DGAT y un agonista de PPAR
US8703962B2 (en) 2008-10-24 2014-04-22 Purdue Pharma L.P. Monocyclic compounds and their use as TRPV1 ligands
US8759362B2 (en) 2008-10-24 2014-06-24 Purdue Pharma L.P. Bicycloheteroaryl compounds and their use as TRPV1 ligands
US8546388B2 (en) 2008-10-24 2013-10-01 Purdue Pharma L.P. Heterocyclic TRPV1 receptor ligands
WO2010064597A1 (ja) * 2008-12-01 2010-06-10 武田薬品工業株式会社 ピペリジン誘導体
GB0902173D0 (en) * 2009-02-10 2009-03-25 Takeda Pharmaceutical Compounds and their use
WO2011162409A1 (en) 2010-06-22 2011-12-29 Shionogi & Co., Ltd. Compounds having trpv1 antagonistic activity and uses thereof

Similar Documents

Publication Publication Date Title
JP2014515349A5 (enExample)
JP2017508789A5 (enExample)
JP2018526367A5 (enExample)
JP2016515560A5 (enExample)
JP2019527203A5 (enExample)
RU2019130519A (ru) 4-пиридоновое соединение или его соль, фармацевтическая композиция и содержащий их состав
JP2013531031A5 (enExample)
JP2016518437A5 (enExample)
JP2016006118A5 (enExample)
JP2014015465A5 (enExample)
JP2012505871A5 (enExample)
JP2016040288A5 (enExample)
RU2018127728A (ru) Слитые трициклические гетероциклические соединения в качестве ингибиторов интегразы вич
JP2005526857A5 (enExample)
CA2662305A1 (en) Heterocyclic gpr40 modulators
JP2012519691A5 (enExample)
JP2016510043A5 (enExample)
JP2006524660A5 (enExample)
RU2013108348A (ru) Конденсированные гетероарилы и их применение
JP2019500387A5 (enExample)
JP2018533593A5 (enExample)
RU2019116590A (ru) Трициклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
MX2020008570A (es) Inhibidores de arginasa y sus metodos de uso.
JP2016531126A5 (enExample)
JP2009518365A5 (enExample)